Suh C H, Oaks M K, Dong N N, Pellegrini J G, Kress D C, Tector A J
Transplant Research Laboratory, St. Luke's Medical Center, Milwaukee, Wisconsin 63215, USA.
J Invest Surg. 1997 Jan-Apr;10(1-2):37-40. doi: 10.3109/08941939709032123.
Rat strains with congenitally reduced total hemolytic complement activity do not reject cardiac xenografts hyperacutely. Prolongation of graft survival in the guinea pig-to-C6-deficient PVG rat donor/recipient combination has been observed. However, experience with this model has been complicated by a high postoperative mortality from respiratory distress. The authors hypothesized that placement of the xenograft resulted in local activation of complement, which contributed to remote pulmonary injury leading to respiratory dysfunction. To test this hypothesis, an attempt was made to reduce early complement component activation with the use of an antibody to rat C3 in C6-deficient PVG recipients. Six of eight untreated C6-deficient PVG recipients died in the immediate postoperative period with vigorously beating heart grafts, whereas only 2 of 14 C6-deficient recipients pretreated with anti-rat C3 antibody died within 24 h postoperatively. Although pretreatment with anti-C3 antibody improved survival of recipients, the duration of cardiac xenograft survival was similar whether the recipients were pretreated or not. The use of anti-C3 antibody in C6-deficient rats is a valid approach to studying xenotransplantation in the absence of hyperacute rejection and has an additional advantage in that it does not require the use of expensive reagents such as cobra venom factor.
先天性总溶血补体活性降低的大鼠品系不会超急性排斥心脏异种移植物。在豚鼠到C6缺陷型PVG大鼠的供体/受体组合中,已观察到移植物存活时间延长。然而,该模型的经验因术后呼吸窘迫导致的高死亡率而变得复杂。作者推测,异种移植物的植入导致补体的局部激活,这导致远处肺损伤,进而导致呼吸功能障碍。为了验证这一假设,研究人员试图通过在C6缺陷型PVG受体中使用抗大鼠C3抗体来减少早期补体成分的激活。8只未治疗的C6缺陷型PVG受体中有6只在术后即刻死亡,心脏移植物仍有力跳动,而14只接受抗大鼠C3抗体预处理的C6缺陷型受体中只有2只在术后24小时内死亡。虽然抗C3抗体预处理提高了受体的存活率,但无论受体是否接受预处理,心脏异种移植物的存活时间相似。在C6缺陷型大鼠中使用抗C3抗体是在无超急性排斥反应的情况下研究异种移植的一种有效方法,并且还有一个额外的优点,即它不需要使用诸如眼镜蛇毒因子等昂贵的试剂。